Gastrointestinal and Liver Adverse Effects of Alcohol Use Disorder Medications: A Pharmacovigilance Analysis.

Clin Gastroenterol Hepatol

Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

Published: January 2025

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2024.12.009DOI Listing

Publication Analysis

Top Keywords

gastrointestinal liver
4
liver adverse
4
adverse effects
4
effects alcohol
4
alcohol disorder
4
disorder medications
4
medications pharmacovigilance
4
pharmacovigilance analysis
4
gastrointestinal
1
adverse
1

Similar Publications

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches.

Dig Dis Sci

January 2025

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Yeman St, Chamran Expressway, P.O. Box 19857-17413, Tehran, Iran.

Colorectal cancer (CRC) is ranked as the second leading cause of cancer-related deaths globally, necessitating urgent advancements in therapeutic approaches. The emergence of groundbreaking therapies, including chimeric antigen receptor-T (CAR-T) cell therapies, oncolytic viruses, and immune checkpoint inhibitors, marks a transformative era in oncology. These innovative modalities, tailored to individual genetic and molecular profiles, hold the promise of significantly enhancing patient outcomes.

View Article and Find Full Text PDF

Phenotypical Characterization of Gastroenterological and Metabolic Manifestations in Patients With Williams-Beuren Syndrome.

Am J Med Genet A

January 2025

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Gastrointestinal (GI) symptoms are common in patients with Williams-Beuren syndrome (WBS), but their prevalence and possible causes are not yet fully known. This study assessed GI symptoms' prevalence and their possible origin by performing a predefined set of tests in adult WBS patients. Laboratory tests and a questionnaire were administered to assess GI symptoms and dietary habits.

View Article and Find Full Text PDF

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been linked to pancreatic diseases, but evidence from population-based studies with liver histology is lacking.

Aims And Methods: In this population-based cohort including all Swedish adults (n = 8563) with biopsy-proven MASLD, we aimed to investigate incidences of pancreatic diseases compared with matched reference individuals from the general population (n = 38,858) and full siblings (n = 6696). Using Cox proportional hazard models, we calculated multivariable adjusted hazard ratios (aHRs) and confidence intervals (CIs).

View Article and Find Full Text PDF

Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers.

Methods: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing.

View Article and Find Full Text PDF

Basidiobolomycosis, a rare fungal infection seen in immunocompetent patients, is a chronic granulomatous infection affecting the skin and subcutaneous tissue. It is caused by the fungus . Gastrointestinal basidiobolomycosis usually has non-specific clinical manifestations, and its diagnosis requires a high index of suspicion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!